A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
751 patients around the world
Available in Brazil, United States
Sanofi
1Research sites
751Patients around the world
This study is for people with
Crohn's disease
Requirements for the patient
To 80 Years
All Gender
Medical requirements
Participants aged ≥18 and ≤80 years of age at Baseline. (Where locally permissible, participants 16 to <18 years of age who meet the definition of Tanner stage 5 for development).
Pivotal Maintenance Sub-Study: Participants who achieved clinical response and completed endoscopy at the end of STARSCAPE-1.
OLE Sub-Study: Participants who complete the Pivotal Maintenance Sub-Study or participation in the TV48574-IMM-20038 Study.
Participants with medical or compliance conditions that are deemed unsuitable for the study by the investigator.
Participants with a known hypersensitivity to duvakitug that makes the participant unsuitable for the study by the investigator.
Sites
Fundação Faculdade Regional de Medicina de São José do Rio Preto
Recruiting
Av. Brg. Faria Lima, 5544 Sao Jose do Rio Preto - Estado de São Paulo 15090-000
